Skip to main content
Premium Trial:

Request an Annual Quote

FDA Clears Abbott Test for CLL Prognosis

NEW YORK (GenomeWeb News) – The US Food and Drug Administration has cleared for marketing Abbott's Vysis CLL FISH Probe Kit for determining the prognosis of patients with chronic lymphocytic leukemia.

The test detects genetic abnormalities in lymphocytes, and according to Abbott is the first FDA-cleared CLL test to aid in prognosis. It includes five probes intended to detect deletion of the LSI TP53, LSI ATM, and LSI D13S319 probe targets and gain of the D12Z3 sequence in peripheral blood specimens from untreated patients with B-cell chronic lymphocytic leukemia.

Abbott noted that the test is not intended for use in selecting therapy or monitoring of residual disease.

More than 15,000 patients are diagnosed with CLL in the US each year.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.